molsidomine has been researched along with Chronic Disease in 25 studies
Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to estimate the influence of long-term treatment with molsidomine on structure, systolic function and neurohormonal parameters in patients with chronic heart failure (CHF)." | 7.70 | [The influence of 3-month treatment with molsidomine on structure, function and some neurohormonal parameters in patients with chronic heart failure treated with digoxin, diuretic and angiotensin converting enzyme inhibitors]. ( Jołda-Mydłowska, B; Kosmala, W; Spring, A; Witkowska, M, 1998) |
| "Acute haemodynamic effects of molsidomine, antianginal drug with vasodilator properties, were evaluated in 12 male patients with chronic congestive heart failure in New York Heart Association functional class 3 or 4 (mean age 56 +/- 7 years; ischemic heart disease in 8 cases, dilated cardiomyopathy in 3 cases, heart disease of combined aetiology in 1 case)." | 7.67 | [Hemodynamic effects of molsidomine in chronic congestive heart failure]. ( Camerini, F; Humar, F; Maras, P; Musitelli, G, 1986) |
| "Molsidomine was unable to significantly attenuate mortality, development of heart failure and morphological damage induced by DAU." | 5.43 | Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings? ( Adamcová, M; Bureš, J; Hroch, M; Jansová, H; Jirkovská-Vávrová, A; Jirkovský, E; Kovaříková, P; Lenčová-Popelová, O; Mazurová, Y; Pokorná, Z; Reimerová, P; Šimůnek, T; Štěrba, M; Vostatková, L, 2016) |
| "To this end, we determined pulmonary prostacyclin synthase (PGIS) gene expression, circulating levels of the stable prostacyclin metabolite 6-keto prostaglandin F(1alpha) (6-keto-PGF(1alpha)), pulmonary endothelin (ET)-1 gene expression, and ET-1 plasma levels in rats exposed to 4 weeks of hypoxia (10% O(2)) in the presence or absence of either the nitric oxide (NO) donor molsidomine (MD, 15 mg/kg/day) or the ET-A receptor antagonist LU135252 (LU, 50 mg/kg/day)." | 3.71 | Increased pulmonary prostacyclin synthesis in rats with chronic hypoxic pulmonary hypertension. ( Blumberg, FC; Lorenz, C; Pfeifer, M; Riegger, GA; Sandner, P; Wolf, K, 2002) |
| "The aim of the study was to estimate the influence of long-term treatment with molsidomine on structure, systolic function and neurohormonal parameters in patients with chronic heart failure (CHF)." | 3.70 | [The influence of 3-month treatment with molsidomine on structure, function and some neurohormonal parameters in patients with chronic heart failure treated with digoxin, diuretic and angiotensin converting enzyme inhibitors]. ( Jołda-Mydłowska, B; Kosmala, W; Spring, A; Witkowska, M, 1998) |
| "Renal gene expression of PDGF-A and PDGF-B was neither affected by 2 or 4 weeks of hypoxia nor by concomitant treatment with LU135252 or molsidomine." | 3.70 | Effects of chronic hypoxia on renal PDGF-A, PDGF-B, and VEGF gene expression in rats. ( Blumberg, FC; Holmer, SR; Krämer, BK; Nabel, C; Pfeifer, M; Riegger, GA; Schweda, A; Schweda, F, 2000) |
| "Acute haemodynamic effects of molsidomine, antianginal drug with vasodilator properties, were evaluated in 12 male patients with chronic congestive heart failure in New York Heart Association functional class 3 or 4 (mean age 56 +/- 7 years; ischemic heart disease in 8 cases, dilated cardiomyopathy in 3 cases, heart disease of combined aetiology in 1 case)." | 3.67 | [Hemodynamic effects of molsidomine in chronic congestive heart failure]. ( Camerini, F; Humar, F; Maras, P; Musitelli, G, 1986) |
| "Molsidomine was unable to significantly attenuate mortality, development of heart failure and morphological damage induced by DAU." | 1.43 | Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings? ( Adamcová, M; Bureš, J; Hroch, M; Jansová, H; Jirkovská-Vávrová, A; Jirkovský, E; Kovaříková, P; Lenčová-Popelová, O; Mazurová, Y; Pokorná, Z; Reimerová, P; Šimůnek, T; Štěrba, M; Vostatková, L, 2016) |
| "4." | 1.32 | The superoxide dismutase mimetic, tempol, blunts right ventricular hypertrophy in chronic hypoxic rats. ( de Dam, MY; Elmedal, B; Mulvany, MJ; Simonsen, U, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (48.00) | 18.7374 |
| 1990's | 6 (24.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 1 (4.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lenčová-Popelová, O | 1 |
| Jansová, H | 1 |
| Jirkovský, E | 1 |
| Bureš, J | 1 |
| Jirkovská-Vávrová, A | 1 |
| Mazurová, Y | 1 |
| Reimerová, P | 1 |
| Vostatková, L | 1 |
| Adamcová, M | 1 |
| Hroch, M | 1 |
| Pokorná, Z | 1 |
| Kovaříková, P | 1 |
| Šimůnek, T | 1 |
| Štěrba, M | 1 |
| Elmedal, B | 1 |
| de Dam, MY | 1 |
| Mulvany, MJ | 1 |
| Simonsen, U | 1 |
| Kuz'ko, NV | 1 |
| Sokolov, AM | 1 |
| Suloeva, MN | 1 |
| Mareev, VIu | 1 |
| Sazonova, LN | 1 |
| Grigor'iants, RA | 1 |
| Lobova, NM | 1 |
| Irani, RM | 1 |
| Hayasaki, K | 1 |
| Tokunaga, M | 1 |
| Kodama, H | 1 |
| Kikuchi, H | 1 |
| Matsunaga, K | 1 |
| Ogata, A | 1 |
| Ogawa, T | 1 |
| Hoffmann, E | 1 |
| Traina, M | 1 |
| Alfano, R | 1 |
| Piraino, GL | 1 |
| Raineri, A | 1 |
| Messin, R | 1 |
| Boxho, G | 1 |
| De Smedt, J | 1 |
| Buntinx, IM | 1 |
| Kukushkin, SK | 1 |
| Shamarin, VM | 1 |
| Manoshkina, EM | 1 |
| Berzak, NV | 1 |
| Petrosian, KIu | 1 |
| Kaeffer, N | 1 |
| Richard, V | 1 |
| François, A | 1 |
| Lallemand, F | 1 |
| Henry, JP | 1 |
| Thuillez, C | 1 |
| Blasini, R | 1 |
| Lehmann, G | 1 |
| Schömig, A | 1 |
| Spring, A | 1 |
| Jołda-Mydłowska, B | 1 |
| Kosmala, W | 1 |
| Witkowska, M | 1 |
| Schweda, F | 2 |
| Blumberg, FC | 4 |
| Schweda, A | 2 |
| Kammerl, M | 1 |
| Holmer, SR | 2 |
| Riegger, GA | 4 |
| Pfeifer, M | 4 |
| Krämer, BK | 2 |
| Nabel, C | 1 |
| Wolf, K | 2 |
| Sandner, P | 2 |
| Lorenz, C | 2 |
| Sousa, AM | 1 |
| Prado, WA | 1 |
| Butorov, IV | 3 |
| Matkovskiĭ, SK | 1 |
| Butorova, VG | 1 |
| Bondarenko, IP | 2 |
| Tkachev, VA | 1 |
| Vorob'ev, LP | 1 |
| Kaziulin, AN | 1 |
| Gavrisiuk, VK | 1 |
| Iachnik, AI | 1 |
| Diachenko, AP | 1 |
| Krasnostup, NA | 1 |
| Morskaia, ND | 1 |
| Zharov, EI | 2 |
| Bodrug, NI | 1 |
| Humar, F | 1 |
| Maras, P | 1 |
| Musitelli, G | 1 |
| Camerini, F | 1 |
2 reviews available for molsidomine and Chronic Disease
| Article | Year |
|---|---|
[Nitric oxide donors in therapy of chronic heart failure].
Topics: Chronic Disease; Drug Tolerance; Heart Failure; Hemodynamics; Humans; Molsidomine; Nitrates; Nitric | 1997 |
[Drug treatment of patients with the chronic form of atrial fibrillation in counterindications for cardioversion (a review)].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anabolic Agents; Atrial Fibrillation; Calcium Channel Block | 1985 |
1 trial available for molsidomine and Chronic Disease
| Article | Year |
|---|---|
Acute and chronic effect of molsidomine extended release on exercise capacity in patients with stable angina, a double-blind cross-over clinical trial versus placebo.
Topics: Acute Disease; Adult; Aged; Angina Pectoris; Blood Pressure; Chronic Disease; Cross-Over Studies; De | 1995 |
22 other studies available for molsidomine and Chronic Disease
| Article | Year |
|---|---|
Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Cell Line, | 2016 |
The superoxide dismutase mimetic, tempol, blunts right ventricular hypertrophy in chronic hypoxic rats.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Administration, O | 2004 |
[Treatment with sidnonimine derivatives of chronic ischemic heart disease patients].
Topics: Angina Pectoris; Arrhythmias, Cardiac; Chronic Disease; Coronary Disease; Drug Evaluation; Female; H | 1984 |
[Effect of korvatone on the hemodynamic indices of rheumatism patients].
Topics: Adult; Aged; Chronic Disease; Drug Evaluation; Heart Failure; Hemodynamics; Humans; Middle Aged; Mol | 1984 |
[Use of the vasodilator molsidomin in the treatment of chronic cardiac insufficiency].
Topics: Administration, Oral; Cardiac Output, Low; Chronic Disease; Female; Hemodynamics; Humans; Injections | 1983 |
[Effects of molsidomine on hemodynamics for the patients with chronic heart failure (author's transl)].
Topics: Aged; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Molsidomine; | 1981 |
[Hemodynamic effects of molsidomine in chronic cardiac decompensation].
Topics: Aged; Chronic Disease; Female; Heart Failure; Humans; Male; Middle Aged; Molsidomine; Oxadiazoles; S | 1981 |
[New drug forms of molsidomine, Corvaton-forte and Corvaton-retard, and their antianginal efficacy in stenocardia patients].
Topics: Angina Pectoris; Chronic Disease; Delayed-Action Preparations; Drug Evaluation; Exercise Test; Femal | 1996 |
Preconditioning prevents chronic reperfusion-induced coronary endothelial dysfunction in rats.
Topics: Acetylcholine; Animals; Chronic Disease; Coronary Circulation; Coronary Vessels; Endothelium, Vascul | 1996 |
[The influence of 3-month treatment with molsidomine on structure, function and some neurohormonal parameters in patients with chronic heart failure treated with digoxin, diuretic and angiotensin converting enzyme inhibitors].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Digoxin; Diuretics; Electrocardiogr | 1998 |
Effects of chronic hypoxia on renal renin gene expression in rats.
Topics: Animals; Blood Pressure; Chronic Disease; Endothelin Receptor Antagonists; Endothelin-1; Endothelin- | 2000 |
Effects of chronic hypoxia on renal PDGF-A, PDGF-B, and VEGF gene expression in rats.
Topics: Animals; Chronic Disease; Endothelial Growth Factors; Endothelin Receptor Antagonists; Gene Expressi | 2000 |
The NO donor molsidomine reduces endothelin-1 gene expression in chronic hypoxic rat lungs.
Topics: Animals; Chronic Disease; Disease Models, Animal; Endothelin-1; Enzyme Inhibitors; Gene Expression R | 2001 |
The dual effect of a nitric oxide donor in nociception.
Topics: Animals; Chronic Disease; Cyclic GMP; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hemoglobi | 2001 |
Increased pulmonary prostacyclin synthesis in rats with chronic hypoxic pulmonary hypertension.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Chronic Disease; Cytochrome P-450 Enzyme System; Endothelin R | 2002 |
[The role of peripheral vasodilators in the treatment of congestive heart failure in chronic cor pulmonale].
Topics: Chronic Disease; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Molsidomine; Nitrog | 1991 |
[The effectiveness of digoxin and sidnofarm in the initial stages of chronic circulatory failure].
Topics: Angina Pectoris; Chronic Disease; Digoxin; Drug Evaluation; Female; Heart Failure; Hemodynamics; Hum | 1989 |
[Indications for the use of molsidomine in patients with chronic cor pulmonale].
Topics: Acid-Base Equilibrium; Adult; Aged; Blood Gas Analysis; Chronic Disease; Drug Evaluation; Female; He | 1988 |
[Possibilities of correcting hemodynamic disorders in patients with chronic obstructive bronchitis].
Topics: Adult; Bronchitis; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Hemodynamics; Humans | 1988 |
[Use of sidnofarm in the treatment of pulmonary-cardiac insufficiency].
Topics: Adult; Bronchitis; Chronic Disease; Humans; Male; Middle Aged; Molsidomine; Pulmonary Heart Disease | 1988 |
[Use of sydnopharm and silabolin in patients with chronic cor pulmonale].
Topics: Anabolic Agents; Bronchitis; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Estrenes; | 1988 |
[Hemodynamic effects of molsidomine in chronic congestive heart failure].
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cardiac Catheterization; Cardiac Output; Chronic | 1986 |